Alexithymia Test (TAS-20 Guide)

What Is Alexithymia?

Alexithymia (from Greek: a- "lack", lexis "words", thymos "emotion") is a personality trait characterized by difficulty in identifying, describing, and distinguishing one's own emotions. The term was coined by Peter Sifneos in the 1970s and is now recognized as a transdiagnostic factor relevant to many mental health and medical conditions.

It is not a formal condition in the DSM-5-TR or ICD-11; it is a dimensional trait present to varying degrees in everyone. Population studies report alexithymia in roughly 10–13% of adults, with higher rates in men than women.

Alexithymia is distinct from not caring about emotions. People with the trait often experience emotions as bodily sensations but lack the cognitive capacity to process and verbalize what they are feeling.

Emotional Awareness Reflection

Rate how much each statement describes you in general. There are no right or wrong answers.

Endorsed patterns (rated 4–5) in the types of statements used to assess alexithymia typically involve themes such as: uncertainty about what emotion one is feeling when physically aroused, difficulty finding words for internal states, preferring to focus on concrete external events rather than inner experience, or being more aware of physical tension than the emotions behind it. These are illustrative examples of the dimensions measured; the actual TAS-20 items are copyrighted and administered under clinical supervision.

TAS-20 Score Interpreter

The Toronto Alexithymia Scale (TAS-20) is the criterion-standard 20-item measure developed by Bagby, Parker, and Taylor. It was introduced in two companion validation papers published in 1994 and has since been translated into many languages. If you have completed a clinical TAS-20 and received a score, use the guide below to interpret it alongside your clinician's assessment.

Three Dimensions of Alexithymia (TAS-20 Subscales)

The TAS-20 measures three theoretically distinct but interrelated dimensions of alexithymia, each captured by a dedicated subscale. Scores on each subscale are summed to produce the total TAS-20 score (range 20–100).

The DIF and DDF subscales have been consistently identified as the strongest contributors to clinically meaningful alexithymia, and both show moderate-to-strong associations with depression and anxiety symptom severity. The EOT subscale shows weaker associations with other emotional-regulation constructs and is the most frequently debated component in the psychometric literature.

All items use a 5-point Likert scale (1 = strongly disagree; 5 = strongly agree). Five items are reverse-scored before summing the total. Internal consistency for the TAS-20 total score was reported as adequate to good in the original validation (Cronbach α ≈ 0.81 in Bagby et al., 1994).

Alexithymia Co-Occurrence & Prevalence

Alexithymia is not rare. A Finnish population study using the TAS-20 in 1,285 adults found an overall prevalence of 13%, with markedly higher rates in men (17%) than women (10%). Advanced age, lower educational level, and lower socioeconomic status were also associated with higher alexithymia scores in that study.

Alexithymia is substantially more prevalent in clinical populations than in the general population. It appears frequently alongside:

• Depression and anxiety — moderate associations between TAS-20 total score and depression severity have been replicated across dozens of samples; the DIF and DDF subscales show the strongest links.
• Somatic symptom presentations — alexithymia is independently associated with higher somatic symptom burden, even after controlling for diagnosed medical conditions, depression, and anxiety.
• Autism spectrum conditions — approximately 50% of autistic adults score in the alexithymia range on the TAS-20, compared with around 5% in neurotypical comparison groups.
• Eating disorders — alexithymia is frequently observed in anorexia nervosa and bulimia nervosa, where difficulty identifying internal states may complicate emotional processing in treatment.
• Substance use disorders — elevated alexithymia has been reported in people with alcohol and other substance use disorders, potentially related to using substances to manage poorly labelled internal states.
• Post-traumatic stress — trauma exposure, particularly childhood trauma, is associated with higher alexithymia scores; the direction of this relationship continues to be studied.

Because alexithymia is a transdiagnostic trait rather than a disorder, it is best understood as a dimension that may complicate the recognition and treatment of other conditions rather than as a diagnosis in its own right.

Alexithymia vs Autism vs Emotional Blunting

These three phenomena are sometimes confused because each involves some form of altered emotional experience, but they are distinct in etiology, phenomenology, and clinical implications.

Alexithymia

Difficulty processing emotions cognitively; may experience bodily sensations without identifying them as emotions. The trait can occur at any intelligence level and is not inherently tied to social-communication differences. A clinician assessing for alexithymia alone would find no diagnostic category in either the DSM-5-TR or ICD-11.

Autism Spectrum Conditions

Often co-occurs with alexithymia (~50% of autistic adults, per a 2019 meta-analysis by Kinnaird et al.); social-communication differences are separate from emotion-processing difficulties. Researchers have argued that some previously attributed characteristics of autism — such as appearing indifferent to others' emotions — may in fact reflect co-occurring alexithymia rather than autism itself. The two constructs can be measured and should be considered independently.

Emotional Blunting

Reduced emotional intensity, rather than difficulty labelling emotions. Emotional blunting is most commonly encountered as a side-effect of antidepressants or antipsychotic medications, and differs from alexithymia in that the emotional response itself is attenuated, not merely difficult to identify or describe. A person with emotional blunting may know they "should" feel something but simply not feel it; a person with alexithymia may feel something but be unable to name or articulate it.

Building Emotional Awareness

Alexithymia exists on a spectrum and, critically, the research literature suggests it is not fixed. Both mindfulness-based practice and structured socio-emotional exercises have been shown to reduce TAS-20 scores in randomized controlled trials.

Approaches that research has examined include:

• Mindfulness-based practice — regular mindfulness exercises, particularly those emphasizing body-scan and interoceptive awareness, have been associated with reductions in DIF and DDF subscale scores. A 2023 randomized controlled trial found that both mindfulness-based and dyadic partner-based practice over 10 weeks reduced TAS-20 scores relative to baseline.
• Emotion-focused psychotherapy — therapies that explicitly train clients to name and differentiate emotions (such as emotion-focused therapy or AEDP) target the DIF/DDF dimensions most directly.
• Body-oriented approaches — interventions emphasizing interoceptive awareness (noticing and labelling internal physical signals as emotions) address the physiological dimension that often underlies alexithymia.
• Psychoeducation — learning an emotion vocabulary, keeping a daily mood log, and practising labelling emotions in low-stakes situations are commonly recommended first steps that can be built into routine care.

Clinicians integrating measurement-based care often track TAS-20 or similar measures over time to gauge whether emotional awareness is shifting in response to treatment. Change is generally gradual; improvements in alexithymia typically lag behind symptom-level changes.

Track Emotional Awareness Over Time

Because alexithymia is a trait-level construct, single-point measurement provides only a snapshot. Tracking scores across multiple time-points — for example, at intake, at three-month review, and at discharge — gives both the clinician and the client a more informative picture of whether emotional awareness is increasing.

When used within a measurement-based care programme, the TAS-20 complements symptom-level tools (such as depression or anxiety screeners) by capturing a process variable: the capacity to recognize and describe the internal states that underlie symptoms. Deterioration on TAS-20 subscales (particularly DIF) may signal that a client is becoming more emotionally avoidant, prompting a clinical conversation before symptom scores worsen.